Efficacy Study of Drug-eluting and Bare Metal Stents in Bypass Graft Lesions

Exclusion Criteria

• •Cardiogenic shock
• •Target lesion located in the native coronary vessels.
• •In-stent restenosis of CABG
• •Target lesion located at internal mammary artery graft or free arterial graft
• •Malignancies or other comorbid conditions (for example severe liver, renal and pancreatic disease) with life expectancy less than 12 months or that may result in protocol non-compliance.
• •Known allergy to the study medications: clopidogrel, rapamycin, paclitaxel, stainless steel.
• •Inability to take clopidogrel for at least 6 months.
• •Pregnancy (present, suspected or planned) or positive pregnancy test.
• •Previous enrollment in this trial.
• •Patient's inability to fully cooperate with the study protocol.